# US 2023/0081382 A1 · Ex Vivo Method for Removal of RCDP

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0081382 A1
- Document ID: US20230081382A1
- Status: Published application
- Kind: A1
- Application number: 17/798,356
- Filed: 2021-02-10
- Published: 2023-03-16
- Earliest claimed: 2020-02-10
- Applicants: NHS Blood & Transplant
- Inventors: David Anstee; Tosti Mankelow; Sara Trompeter
- Web page: https://patentgrep.com/patent/US20230081382A1

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61M 1/3496: {Plasmapheresis; Leucopheresis; Lymphopheresis (A61M1/3472 takes precedence)}
- A61M 1/3687: {Chemical treatment (A61M1/3675 takes precedence)}
- A61M 1/38: Removing constituents from donor blood and {storing or} returning remainder to body {, e.g. for transfusion}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- B01D 15/3809: {of the antigen-antibody type, e.g. protein A, G or L chromatography}
- A61M 2202/0415: Plasma
- A61M 2202/0429: Red blood cells; Erythrocytes
- A61M 2202/0435: Neocytes, e.g. reticulocytes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing red cell-derived particles (RCDP) from plasma.

## Claims

### Claim 1

A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing red cell-derived particles (RCDP) from plasma isolated from a subject to provide modified plasma.

### Claim 2

A method of decreasing hypercoagulability, increasing plasma clotting time, and/or treating a haemoglobinopathy, haemolytic anaemia or an erythrocyte membrane disorder in a subject, wherein the method comprises:
(i) isolating plasma from the subject;
(ii) removing RCDP from the plasma to provide modified plasma; and
(iii) administering the modified plasma to the subject.

### Claim 3 (depends on 1, 2)

A method according to any one of claims 1 to 2, wherein the RCDP comprise or consist of erythrocyte or reticulocyte-derived micelles, vesicles and/or membrane fragments.

### Claim 4 (depends on 1, 2, 3)

A method according to any one of claims 1 to 3, wherein the RCDP have on their surface one or more markers from the membrane of erythrocytes or reticulocytes, preferably wherein the one or more markers are from the extracellular membrane surface of erythrocytes or reticulocytes.

### Claim 5 (depends on 1, 2, 3, 4)

A method according to any one of claims 1 to 4, wherein the RCDP have on their surface one or more types of blood group active protein.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A method according to any one of claims 1 to 5, wherein the RCDP have on their surface one or more types of blood group active protein selected from the list consisting of: Glycophorin A (GPA), anion exchanger 1 (AE1), glucose transporter 1 (GLUT1), and Glycophorin C (GPC), preferably wherein the RCDP have on their surface GPA.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

A method according to any one of claims 1 to 6, wherein the RCDP have a particle diameter of from 0.1 μm to 12 μm, preferably 1.2 μm to 12 μm, more preferably 3 μm to 12 μm.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A method according to any one of claims 1 to 7, wherein the RCDP have a median particle diameter of 3-12 μm, preferably 6-9 μm or 6-8 μm, more preferably about 7 μm.

### Claim 9

A method of decreasing hypercoagulability and/or increasing plasma clotting time comprising removing vesicles which express on their surface the extracellular and/or cytoplasmic domain of GPA and have a median diameter of 6-9 μm, 6-8 μm, or about 7 μm, from plasma isolated from a subject, to provide modified plasma.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method according to any one of claims 1 to 9, wherein the RCDP have on their surface phosphatidylserine (PS).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A method according to any one of claims 1 to 10, wherein the RCDP are removed by affinity chromatography and/or size exclusion chromatography.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method according to any one of claims 1 to 11, wherein the RCDP are removed by a molecule which selectively binds one or more markers expressed on the surface of the RCDP.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the molecule is an antibody or an antibody fragment, preferably an antibody.

### Claim 14 (depends on 12, 13)

A method according to claim 12 or claim 13, wherein the molecule is immobilised.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A method according to any one of claims 1 to 11, wherein the RCDP are removed by filtration.

### Claim 16 (depends on 15)

A method according to claim 15, wherein the filter has a filter size of 0.1-2 μm, 0.5-2 μm, 0.8-1.6 μm, or 1.0-1.5 μm, preferably about 1.2 μm.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method according to any one of claims 1 to 16, wherein 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or about 100% of the RCDP are removed, preferably about 90% or more of the RCDP are removed.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

A method according to any one of claims 1 to 17, wherein the modified plasma has 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 10% or less RCDP compared to the plasma, preferably 10% or less RCDP compared to the plasma.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

A method according to any one of claims 1 to 18, wherein the modified plasma is substantially free of RCDP.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method according to any one of claims 1 to 19, wherein the modified plasma has a clotting time at least two times longer than the plasma, preferably at least three times longer than the plasma, most preferably at least five times longer than the plasma.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A method according to any one of claims 1 to 20, wherein the modified plasma has a clotting time approximately the same as the clotting time for control plasma from a healthy subject.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A method according to any one of claims 1 to 21, wherein the plasma is isolated from a subject with a haemoglobinopathy, haemolytic anaemia and/or an erythrocyte membrane disorder.

### Claim 23 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

A method according to any one of claims 2 to 22, wherein the haemoglobinopathy is sickle cell disease, preferably wherein the sickle cell disease is sickle cell anaemia, HbSβ-thalassemia, or HbSC disease, more preferably wherein the sickle cell disease is sickle cell anaemia.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

A method according to any one of claims 1 to 23, wherein the plasma is platelet-free plasma and/or the plasma is fresh plasma or fresh frozen plasma.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Modified plasma obtained or obtainable by a method according to any one of claims 1 to 24.

### Claim 26

Plasma which is substantially free of RCDP which express the extracellular domain of GPA on their surface and have a median diameter of 6-9 μm or about 7 μm.

### Claim 27 (depends on 26)

Plasma according to claim 26, wherein the plasma is fresh plasma or fresh frozen plasma.

### Claim 28

An affinity column comprising a stationary phase which specifically binds one or more markers expressed on the surface of RCDP.

### Claim 29 (depends on 28)

An affinity column according to claim 28 wherein the one or more markers are from the extracellular and/or intracellular membrane surface of erythrocytes or reticulocytes, preferably the one or more markers are from the extracellular membrane surface of erythrocytes or reticulocytes.

### Claim 30 (depends on 28, 29)

An affinity column according to claim 28 or claim 29 wherein the one or more markers are selected from the list consisting of: GPA, AE1, GLUT1, GPC, and PS.

### Claim 31 (depends on 28, 29, 30)

An affinity column according to any one of claims 28 to 30 wherein the marker is the extracellular and/or cytoplasmic domain of GPA.

### Claim 32 (depends on 28, 29, 30, 31)

An affinity column according to any one of claims 28 to 31 wherein the molecule is an antibody or an antibody fragment, preferably an antibody.

### Claim 33 (depends on 28, 29, 30, 31, 32)

An apheresis device or an apheresis kit comprising a molecule or a bead which specifically binds one or more antigens markers expressed on the surface of RCDP, and/or an affinity column according to any one of claims 28 to 32.

### Claim 34 (depends on 28, 29, 30, 31, 32, 33)

Use of a molecule or a bead which specifically binds one or more antigens markers expressed on the surface of RCDP, an affinity column according to any one of claims 28 to 32, an apheresis device or an apheresis kit according to claim 33, for removing RCDP, for decreasing hypercoagulability, and/or for increasing plasma clotting time.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 28, 29, 30, 31, 32, 33)

Use of a molecule or a bead which specifically binds one or more antigens markers expressed on the surface of RCDP, an affinity column according to any one of claims 28 to 32, or an apheresis device or an apheresis kit according to claim 33, in a method according to any one of claims 1 to 24.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 34, 35)

A method according to any one of claims 1 to 24, or use according to claim 34 or claim 35, wherein the plasma clotting time is the Factor Xa-activated clotting time, the thrombin time, the activated partial thromboplastin time, the prothrombin time, or the activated clotting time, preferably the plasma clotting time is the Factor Xa-activated plasma clotting time.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 34, 35, 36)

A method according to any one of claims 1 to 24 or claim 36, or use according to any one of claims 34 to 36, wherein the plasma clotting time is increased by at least two-fold, at least three-fold, or at least five-fold.
